According researchers at the University of Gothenburg, for patients who recently received a diagnosis, discovery of glaucoma could mean they start treatment with daily eye drops that lower the pressure in the eye and slow down the damage to the optic nerve.
Targeting the interleukin-11 receptor, LASN01 is a potential treatment for fibro-inflammatory diseases including thyroid eye disease (TED) and idiopathic pulmonary fibrosis (IPF).
The Ophthalmic World Leaders (OWL) Leadership Summit, scheduled for September 21 and 22, 2023, in Austin, Texas, will feature a lineup of prominent speakers and engaging discussions on a wide range of leadership topics and industry insights.
Debbie Allen, an award-winning actress, dancer, choreographer, singer-songwriter, director and producer is teaming up with Prevent Blindness and Regeneron for the Gr8 Eye Movement, an awareness campaign that aims to educate and encourage those who are at risk of certain retinal diseases to prioritize their eye health.
In this key role, Weil will lead the organization to commercial readiness from designing launch strategies for the US and globally.
According to the company, OPGx-LCA5 is designed to address vision loss due to Leber congenital amaurosis associated with mutations in the LCA5 gene, which causes one of the most severe early-onset retinal dystrophies.
Through its #isee4$1 campaign, the organization is helping to bring sight to Cambodia.
The study examines the effectiveness of PL9643 for the treatment of patients with dry eye disease.
According to the companies, the collaboration has the potential to benefit patients who have suffered from specific, chronic ocular diseases.
The trial is for the MINIject MIGS device for patients with primary open-angle glaucoma.
The company is expanding its patent portfolio to 10 granted patents and 32 pending patent applications.
The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.
A new survey shows that 95% of adults at risk for certain retinal diseases know a little or nothing about them. Allen hopes her story will help raise awareness and encourage those at risk to regularly prioritize their eye health.
Jeff Todd talks about the campaign and partnering with actress Debbie Allen to help gain awareness on eye health.
The system is a next generation aqueous shunt therapy for patients with moderate to severe glaucoma.
According to the company, 4D-150 comprises its customized and evolved intravitreal vector, R100, and a transgene cassette that expresses both aflibercept and a VEGF-C inhibitory RNAi.
According to the company, Steven Fusco will focus on Bruder Healthcare and Hilco Vision product portfolios.
AnnMarie Hipsley, DPT, PhD, sat down to speak about founding iAware, a non-for-profit organization established for the promotion of awareness of age-related ocular disease.
According to the company, the deal expands its European footprint into Spain and Portugal.
The beauty brand announces Ashley Brissette, MD, MSc, FRCSC, will be the brand's first guiding ophthalmologist.
According to the company, NFS-05, utilizes a gene therapy approach that delivers an AAV vector containing the OPA1 gene into the vitreous cavity.
The 6-month-old boy’s dark brown eyes turned deep blue after he was treated for COVID with favipiravir.
Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
According to the company, the tool provides free access to training and mentors for eye care professionals in areas with the greatest need, and the new Cybersight mobile app expands access for eye care professionals through offline functionality.
Physician has blazed career path in ophthalmology, breaking glass ceiling.
The estate of James Sams, filed a lawsuit against Lowrey King, MD, Roper St Francis Healthcare, The Retina Eye Center of Charleston, and Carolina Eye Care Physicians in a South Carolina court.
Study demonstrates power of IRIS Registry for evaluation of safety, efficacy
Laura Kopplin, MD, PhD, spoke with our team to share insights from her presentation at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.
.png "Optometry Times"){kind=logo}
